Table 4 Multivariable analysis for progression-free and overall survival (<70 and ≥70 years)^a

Gender (reference; female)

Female vs Male

HR 1.00 (95% CI 0.84–1.18, P = 0.98)

HR 1.14 (95% CI 0.83–1.56, P = 0.42)

HR 1.12 (95% CI 0.94–1.33, P = 0.22)

HR 1.33 (95% CI 0.97–1.84, P = 0.08)

ECOG performance status (reference; 0)

0 vs 1

HR 1.10 (95% CI 0.92–1.32)

HR 0.86 (95% CI 0.60–1.24)

HR 1.08 (95% CI 0.90–1.31)

HR 0.81 (95% CI 0.57–1.16)

0 vs 2

HR 1.58 (95% CI 1.13–2.20)

[P = 0.04]

HR 1.03 (95% CI 0.58–1.83)

[P = 0.65]

HR 2.02 (95% CI 1.45–2.82)

[P = 0.001]

HR 1.84 (95% CI 1.03–3.28)

[P = 0.02]

Disease stage (reference; locally advanced)

Locally advanced vs Metastatic

HR 1.46 (95% CI 1.20–1.78, P < 0.001)

HR 1.21 (95% CI 0.86–1.69, P = 0.28)

HR 1.48 (95% CI 1.20–1.82, P < 0.001)

HR 1.49 (95% CI 1.05–2.12, P = 0.03)